TMED Stock Overview
Engages in the development of psychedelic drugs for the treatment of mental health.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
EGF Theramed Health Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.14 |
| 52 Week High | CA$0.55 |
| 52 Week Low | CA$0.14 |
| Beta | -2.61 |
| 1 Month Change | -3.45% |
| 3 Month Change | -6.67% |
| 1 Year Change | -65.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| TMED | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | 1.7% | 1.1% |
| 1Y | -65.0% | 64.6% | 10.8% |
Return vs Industry: TMED underperformed the Canadian Pharmaceuticals industry which returned 64.6% over the past year.
Return vs Market: TMED underperformed the Canadian Market which returned 10.8% over the past year.
Price Volatility
| TMED volatility | |
|---|---|
| TMED Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 14.4% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CA Market | 17.8% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: TMED's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine TMED's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Connor Yuen | www.egftheramedhealth.com |
EGF Theramed Health Corp. engages in the development of psychedelic drugs for the treatment of mental health. It offers psychedelics for the treatment of conditions, such as treatment-resistant depression, anxiety, PTSD, and depression, as well as natural health and wellness products. The company is headquartered in Vancouver, Canada.
EGF Theramed Health Corp. Fundamentals Summary
| TMED fundamental statistics | |
|---|---|
| Market cap | CA$1.59m |
| Earnings (TTM) | -CA$322.44k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.9x
P/E RatioIs TMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TMED income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$322.44k |
| Earnings | -CA$322.44k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -39.4% |
How did TMED perform over the long term?
See historical performance and comparison